{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:48:17Z","timestamp":1787773697431,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Social Science University of Ankara"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>High maximum standardized uptake value (SUVmax) is associated with poorly differentiated tumors and lymph node metastasis. It is still controversial which tumors can be treated with sublobar resection and there are publications stating that SUVmax of the tumor may be important in choosing sublobar resection. Our aim in this study is to examine the prognostic value of tumor SUVmax in stage 1 non-small cell lung cancer and to determine its place in sublobar resection preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 314 patients who underwent wedge resection, segmentectomy or lobectomy for pathological stage I NSCLC with tumor size\u2009\u2264\u20093\u00a0cm between January 2008 and December 2020. SUVmax of the tumors are dichotomized according to ROC threshold value 5.2 and prognostic factors for recurrence-free and overall survival were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the multivariate survival analysis, SUVmax (p\u2009=\u20090.012), lymphovascular and\/or perineural invasion (p\u2009&lt;\u20090.001) and visceral pleural invasion (p\u2009=\u20090.031) were found to be independent prognostic factors for recurrence-free survival; age (p\u2009=\u20090.027), sex (p\u2009=\u20090.010) and SUVmax (p\u2009=\u20090.036) for overall survival. While there was no difference between lobar or sublobar resection in terms of recurrence-free survival (p\u2009=\u20090.647) in patients with SUVmax\u2009\u2264\u20095.2, lobectomy was found to be advantageous over sublobar resection for recurrence-free survival in patients with SUVmax\u2009&gt;\u20095.2 (76.6%\u2009\u00b1\u20093.9% \/ 53.4%\u2009\u00b1\u200912.1%, p\u2009=\u20090.006, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High SUVmax (&gt;\u20095.2) is associated with poor recurrence-free survival and overall survival rates in pathological stage 1 NSCLC patients. In stage 1 patients, sublobar resection should be avoided if the primary tumor has a high SUVmax.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-025-02049-0","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:45:26Z","timestamp":1744289126000},"page":"792-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Suvmax of the lesion should be considered in the treatment plan for stage I non-small cell lung cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-264X","authenticated-orcid":false,"given":"G\u00f6khan","family":"Kocaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Ibrah\u0131mov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Kahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla Halil","family":"Elhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"En\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-u","volume":"60","author":"RJ Ginsberg","year":"1995","unstructured":"Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615\u201322. https:\/\/doi.org\/10.1016\/0003-4975(95)00537-u.","journal-title":"Ann Thorac Surg"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","volume":"399","author":"H Saji","year":"2022","unstructured":"Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399:1607\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(21)02333-3.","journal-title":"Lancet"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMoa2212083","volume":"388","author":"N Altorki","year":"2023","unstructured":"Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. N Engl J Med. 2023;388:489\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2212083.","journal-title":"N Engl J Med"},{"key":"2049_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.athoracsur.2021.06.017","volume":"113","author":"AN Blumenthaler","year":"2022","unstructured":"Blumenthaler AN, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, et al. Preoperative maximum standardized uptake value associated with recurrence risk in early lung cancer. Ann Thorac Surg. 2022;113:1835\u201344. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.06.017.","journal-title":"Ann Thorac Surg"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ejcts\/ezae347","volume":"66","author":"S Shiono","year":"2024","unstructured":"Shiono S, Endo M, Watanabe H, Takamori S, Suzuki J. Better survival with lobectomy versus sublobar resection in patients with hypermetabolic c-stage IA lung cancer on positron emission tomography\/computed tomography. Eur J Cardiothorac Surg. 2024;66:347. https:\/\/doi.org\/10.1093\/ejcts\/ezae347.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/ejcts\/ezaa231","volume":"58","author":"A Kamigaichi","year":"2020","unstructured":"Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Ito H, Nakayama H, et al. Prognosis of segmentectomy and lobectomy for radiologically aggressive small-sized lung cancer. Eur J Cardiothorac Surg. 2020;58:1245\u201353. https:\/\/doi.org\/10.1093\/ejcts\/ezaa231.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/JTO.0b013e3181b6be3e","volume":"4","author":"SW Um","year":"2009","unstructured":"Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2009;4:1331\u20136. https:\/\/doi.org\/10.1097\/JTO.0b013e3181b6be3e.","journal-title":"J Thorac Oncol"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtcvs.2004.11.007","volume":"130","author":"RJ Cerfolio","year":"2005","unstructured":"Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151\u20139. https:\/\/doi.org\/10.1016\/j.jtcvs.2004.11.007.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2049_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146195","volume":"1","author":"J Liu","year":"2016","unstructured":"Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET\/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS ONE. 2016;1: e0146195. https:\/\/doi.org\/10.1371\/journal.pone.0146195.","journal-title":"PLoS ONE"},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/JTO.0b013e3181d0a4f5","volume":"5","author":"M Paesmans","year":"2010","unstructured":"Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5:612\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e3181d0a4f5.","journal-title":"J Thorac Oncol"},{"key":"2049_CR11","doi-asserted-by":"publisher","unstructured":"Bayarri-Lara CI, de Miguel P\u00e9rez D, Cueto Ladr\u00f3n de Guevara A, Rodriguez Fern\u00e1ndez A, Puche JL, S\u00e1nchez-Palencia Ramos A, et al. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. Eur J Cardiothorac Surg. 2017;52:55\u201362. https:\/\/doi.org\/10.1093\/ejcts\/ezx049.","DOI":"10.1093\/ejcts\/ezx049"},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/JTO.0b013e3181f9abca","volume":"6","author":"S Shiono","year":"2011","unstructured":"Shiono S, Abiko M, Sato T. Positron emission tomography\/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers. J Thorac Oncol. 2011;6:43\u20137. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f9abca.","journal-title":"J Thorac Oncol"},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cllc.2021.10.004","volume":"23","author":"J Li","year":"2022","unstructured":"Li J, Wang Y, Li J, Cao S, Che G. Meta-analysis of lobectomy and sublobar resection for stage I non-small cell lung cancer with spread through air spaces. Clin Lung Cancer. 2022;23:208\u201313. https:\/\/doi.org\/10.1016\/j.cllc.2021.10.004.","journal-title":"Clin Lung Cancer"},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00408-023-00649-z","volume":"201","author":"N Motono","year":"2023","unstructured":"Motono N, Mizoguchi T, Ishikawa M, Iwai S, Iijima Y, Uramoto H. Prognostic \u0131mpact of cancer \u0131nflammation prognostic \u0131ndex for non-small cell lung cancer. Lung. 2023;201:603\u201310. https:\/\/doi.org\/10.1007\/s00408-023-00649-z.","journal-title":"Lung"},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1007\/s00330-021-07801-4.9","volume":"31","author":"HP Chou","year":"2021","unstructured":"Chou HP, Lin KH, Huang HK, Lin LF, Chen YY, Wu TH, et al. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer. Eur Radiol. 2021;31:8021\u20139. https:\/\/doi.org\/10.1007\/s00330-021-07801-4.9.","journal-title":"Eur Radiol"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JTO.0b013e318160c122","volume":"3","author":"B Goodgame","year":"2008","unstructured":"Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol. 2008;3:130\u20134. https:\/\/doi.org\/10.1097\/JTO.0b013e318160c122.","journal-title":"J Thorac Oncol"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.athoracsur.2023.04.013","volume":"117","author":"LF Tapias","year":"2024","unstructured":"Tapias LF, Shen R, Cassivi SD, Reisenauer JS, Lunn BW, Lechtenberg BJ, et al. Impact of FDG PET standardized uptake value in resected clinical stage Ia non-small cell lung cancer. Ann Thorac Surg. 2024;117:1017\u201323. https:\/\/doi.org\/10.1016\/j.athoracsur.2023.04.013.","journal-title":"Ann Thorac Surg"},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2021.12.007","volume":"164","author":"S Zhang","year":"2022","unstructured":"Zhang S, Lin D, Yu Y, Cao Q, Liu G, Jiang D, et al. Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax? Lung Cancer. 2022;164:14\u201322. https:\/\/doi.org\/10.1016\/j.lungcan.2021.12.007.","journal-title":"Lung Cancer"},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/RLU.0000000000003714","volume":"46","author":"D Tosi","year":"2021","unstructured":"Tosi D, Pieropan S, Cattoni M, Bonitta G, Franzi S, Mendogni P, et al. Prognostic value of 18F-FDG PET\/CT metabolic parameters in surgically treated stage I lung adenocarcinoma patients. Clin Nucl Med. 2021;46:621\u20136.","journal-title":"Clin Nucl Med"},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/cam4.2900","volume":"9","author":"S Wang","year":"2020","unstructured":"Wang S, Lin D, Yang X, Zhan C, Zhao S, Luo R, et al. Clinical significance of PET\/CT uptake for peripheral clinical N0 non-small cell lung cancer. Cancer Med. 2020;9:2445\u201353. https:\/\/doi.org\/10.1002\/cam4.2900.","journal-title":"Cancer Med"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00259-009-1291-x","volume":"37","author":"M Agarwal","year":"2010","unstructured":"Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691\u20138. https:\/\/doi.org\/10.1007\/s00259-009-1291-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2049_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2214\/AJR.19.21585","volume":"214","author":"X Shao","year":"2020","unstructured":"Shao X, Niu R, Jiang Z, Shao X, Wang Y. Role of PET\/CT in management of early lung adenocarcinoma. AJR Am J Roentgenol. 2020;214:437\u201345. https:\/\/doi.org\/10.2214\/AJR.19.21585.","journal-title":"AJR Am J Roentgenol"},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ejcts.2008.12.030","volume":"35","author":"HR Kim","year":"2009","unstructured":"Kim HR, Kim DJ, Lee WW, Jheon S, Sung SW. The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. Eur J Cardiothorac Surg. 2009;35:712\u20136. https:\/\/doi.org\/10.1016\/j.ejcts.2008.12.030.","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02049-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:25:38Z","timestamp":1757157938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02049-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5820876\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest with respect to the authorship and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Ankara University Human Research Ethics Committee (date: 15.05.2020, no: \u01304-240\u201320). Written informed consent was waived by the committee because of the retrospective design of the study and the absence of a condition indicating the identities of the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}